



SUPPLEMENTARY DATA

Supplementary Figure 1. (a) Nuclear fractions of aorta samples from non diabetic WT or hAR transgenic mice were analyzed by western blot for expression of Egr-1. (b) Expression of Egr-1 in aorta collected from apoE^{-/-}-hAR treated with streptozotocin. The tissues were extracted after 8, 10, 12 and 14 weeks of treatment with streptozotocin. Results are representative of 5 mice per group.




Supplementary Figure 2. Total HAT activity measured using assay kit (Activ Motif, USA) (Cat#56100) in MAECs. The figure represents percent total HAT activity in HAECs treated with low glucose, high glucose, high glucose along with ARI and high glucose with SDI.



SUPPLEMENTARY DATA

Supplementary Figure 3. Expression of acetylated Egr-1 in MAECs over expressing hAR, treated with low glucose along with FK (NAMPT inhibitor) for 4 hrs.



Supplementary Figure 4. Expression of acetylated Egr-1 in HAECs treated with low glucose along with high glucose; HAEC over expressing sirt 1 or GFP at high glucose and HAEC treated with DMSO or SRT1720(10uM) an activator of sirt1 for 5hrs. The figure shows a representation of at least three independent experiments.

